- TLDR Biotech
- Archive
- Page -30
The Latest Biotech & Pharma Updates
Biotech & Pharma Updates | October 7 - 8, 2025
🧬 Nilo Tx launches with $101M to target the "body-brain circuit", Sanofi touts positive Ph2 radiopharma data in neuroendocrine tumors, Sanofi + BenchSci partner on AI-powered preclinical research platform, TransCode acquires Polynoma + secures $25M funding to advance phase 3 cancer vaccine, Regeneron's Libtayo PD-1 inhibitor lands FDA adjuvant therapy approval in squamous cell carcinoma, UK government considers raising NICE cost-effectiveness threshold to increase NHS drug spending
Biotech & Pharma Updates | October 6 - 7, 2025
🧬 Soufflé Therapeutics rises to the occasion with $200M for siRNA therapies, MapLight seeks $227M IPO for neuropsychiatric drug development portfolio, FDA approves Boehringer Ingelheim's jascayd PDE4 inhibitor in idiopathic pulmonary fibrosis, GEMMABio launches RareTx spin-out focused on ultra-rare orphan diseases, OXB purchases US viral vector site from National Resilience, Boehringer + MOLCURE AI-powered mAbs discovery and development pact, BlueRock Tx touts positive Ph1 cell therapy data in Parkinson's
Biotech & Pharma Updates | October 5 - 6, 2025
🧬 TCG Crossover raises $1.3B third fund focused on biotech + life sciences, AstraZeneca + Daiichi Sankyo's Datroway shows survival benefit vs chemotherapy in Ph3 triple-negative breast cancer trial, Trogenix's "Trojan Horse"-tech for cancer biotech lands £70M Series A, AstraZeneca + Algen sign up to $555M AI-powered drug discovery partnership, Chiesi + Arbor up to $2.1B rare disease partnership, Eli Lilly to invest up to $1B in Indian-based CDMO partnerships
Biotech & Pharma Updates | October 2 - 5, 2025
🧬 Cidara lands up to $339M BARDA contract for non-vaccine flu prevention, Ovid reports positive Ph1 data in drug-resistant epilepsy, FDA launches generics priority review program for domestic manufacturing, GSK comes out on top in UK PMCPA marketing scuffle, Palisade Bio closes $138M public offering fuelling IBD ambitions
Biotech & Pharma Updates | October 1 - 2, 2025
🧬 Jazz Pharma + PharmaMar's Zepzelca approved for first-line maintenance treatment in extensive-stage small-cell lung cancer, Cartography's $67M Series B in pursuit of “differentiated” cancer drugs, Amgens touts "landmark" Ph3 win for PCSK9 inhibitor in cardiovascular event prevention, Pfizer + C4 Therapeutics sign clinical trial + supply agreement, Vaxcyte's up to $1B Thermo Fisher deal for fill-finish space access, Daiichi Sankyo opens third international R&D site (this one in San Diego)
Biotech & Pharma Updates | September 30 - October 1, 2025
🧬 Who's who of big pharma pools data in bid for better AI models, Halozyme expands subcutaneous delivery reach with up to $900M Elektrofi acquisition, AbbVie unveils $70M investment in Massachusetts bioresearch center, Ansa's $54.4M Series B to fuel DNA synthesis ambitions, Novartis nabs FDA approval first in oral BTK blocker for chronic spontaneous urticaria, Trump admins delays 100% tariff on branded pharmaceuticals
Biotech & Pharma Updates | September 29 - 30, 2025
🧬 Pfizer first to embrace MFN drug pricing + DTC via upcoming "TrumpRx" website, Merck & Co. published positive Winrevair Ph3 data in pulmonary arterial hypertension, Barinthus Therapeutics + Clywedog Therapeutics reverse merger, Rovi to acquire Phoenix-based BMS facility, AstraZeneca to "harmonize its share listing structure" via direct NYSE listing, EMA publishes draft guidance on including patient perspective in drug approval process
Biotech & Pharma Updates | September 28 - 29, 2025
🧬 Genmab ponies up $8B for Merus acquisition - eyes bispecific cancer assets, AstraZeneca + Daiichi Sankyo's Enhertu ADC beats Roche's Kadcyla in early breast cancer trial, Gilead in-licenses Health Hope Pharma's P-gp inhibitor in virology space for $10M upfront + $72.5M biobucks, FDA approves J&J's Tremfya in pediatric plaque psoriasis, Star Therapeutics lands $125M Series D for bleeding disorder aspirations, Full-Life Technologies $77M Series C + debt financing for radiopharma aspirations
Biotech & Pharma Updates | September 25 - 28, 2025
🧬 AstraZeneca joins direct-to-consumer fray with Oct 1 platform launch, Sanofi caps all insulin products in the US to $35/month (regardless of insurance), Amgen commits $650M to Puerto Rico site expansion, Eli Lilly opens biotech incubator in San Diego (able to fit up to 15 companies & 250 employees), Lotus buys-out Alvogen for up to $2B, Cure Alzheimer's Fund receives $50M gift to support research, FDA approves Regeneron's ANGPTL3 antibody to treat children 1 - 5 years of age with homozygous familial hypercholesterolemia
Biotech & Pharma Updates | September 24 - 25, 2025
🧬 FDA draft docs for faster CGT drug development, Eli Lilly lands a pair of approvals (FDA approval for oral SERD in breast cancer + EC approval for Kisunla in early symptomatic Alzheimer's), Merck & Co. in-licenses Evaxion's AI-platform based vaccine candidate for $7.5M upfront + $592M biobucks, NIH pledges $87M for organoid center in accelerating shift away from animal testing, UK may attempt big pharma damage control by "fix[ing] the commercial environment" (raising prescription drug prices)
Biotech & Pharma Updates | September 23 - 24, 2025
🧬 uniQure's Huntington's gene therapy slows down disease progression by 75% over 3 years in Ph2 trial, Glenmark signs up to $1B ADC deal with Hengrui Pharma, Roche presents new Ocrevus data with "significant benefit" in preventing MS-related disability progress, Moderna opens new UK vaccine manufacturing/R&D site amongst other big pharma exits, Fujifilm Biotechnologies opens doors to new $3.2B facility as one of the "largest cell culture biomanufacturing sites in the U.S.", Sparrow Pharmaceuticals lands $95M Series B to help T2D patients with elevated cortisol
Biotech & Pharma Updates | September 22 - 23, 2025
🧬 Eli Lilly drops $6.5B on Houston API plant, BMS' multiple myeloma protein degrader iberdomide hits a Ph3 goal, Merck & Co. commits further $349M into Variational AI drug discovery partnership, atai Life Sciences & Beckley Psytech report positive Ph2a data for DMT analog in treatment resistant depression, Sanofi commits further $625M into venture investment arm Sanofi Ventures, Manas AI touts $26M seed extension for "full-stack, AI native drug discovery and development"